title: Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death.
abstract: Docetaxel (DTX) is one of the most important anticancer drugs; however, the severity of its adverse effects detracts from its practical use in the clinic. Magnetic nanoparticles of Fe3O4 (MgNPs-Fe3O4) can enhance the delivery and efficacy of anticancer drugs. We investigated the effects of MgNPs-Fe3O4 or DTX alone, and in combination with prostate cancer cell growth in vitro, as well as with the mechanism underlying the cytotoxic effects. MgNPs-Fe3O4 caused dose-dependent increases in reactive oxygen species levels in DU145, PC-3, and LNCaP cells; 8-hydroxydeoxyguanosine levels were also elevated. MgNPs-Fe3O4 alone reduced the viability of LNCaP and PC-3 cells; however, MgNPs-Fe3O4 enhanced the cytotoxic effect of a low dose of DTX in all three cell lines. MgNPs-Fe3O4 also augmented the percentage of DU145 cells undergoing apoptosis following treatment with low dose DTX. Expression of nuclear transcription factor κB in DU145 was not affected by MgNPs-Fe3O4 or DTX alone; however, combined treatment suppressed nuclear transcription factor κB expression. These findings offer the possibility that MgNPs-Fe3O4-low dose DTX combination therapy may be effective in treating prostate cancer with limited adverse effects.
authors.affiliation: Laboratory for Medical Engineering, Division of Materials Science and Chemical Engineering, Graduate School of Engineering, Yokohama National University, Yokohama, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Sato
authors.forename: Naoki
authors.initials: N
authors.lastname: Itcho
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Daiki
authors.initials: D
authors.lastname: Okamoto
authors.forename: Naohito
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kawai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kasai
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kurioka
authors.forename: Hiroji
authors.initials: H
authors.lastname: Uemura
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Watanabe
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004247:DNA / Q000737:chemistry; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000032:analysis; D000077143:Docetaxel; D006801:Humans; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000378:metabolism; D043823:Taxoids / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D058185:Magnetite Nanoparticles; D016328:NF-kappa B; D017382:Reactive Oxygen Species; D043823:Taxoids; D000077143:Docetaxel; D000080242:8-Hydroxy-2'-Deoxyguanosine; D004247:DNA; D003849:Deoxyguanosine
keywords: docetaxel; magnetic nanoparticles; prostate cancer; reactive oxidative species